Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01286480
Other study ID # AM-Chapter-01
Secondary ID
Status Completed
Phase N/A
First received January 27, 2011
Last updated June 23, 2017
Start date January 2011
Est. completion date December 2013

Study information

Verified date June 2017
Source University of Alberta
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to evaluate the potential role of a cardiology clinic-based educational intervention for 15 to 17 year olds with congenital heart disease (CHD) and their parents, and to determine whether this intervention results in improved self-management skills (e.g., renewing medication prescriptions), teens having greater knowledge of their heart condition, and more teen and parent satisfaction with services. The results of this study will form the basis for a website that in turn may serve as an additional means of providing transition interventions. The results of this study may also be applicable to youth with other special health care needs.


Recruitment information / eligibility

Status Completed
Enrollment 66
Est. completion date December 2013
Est. primary completion date November 2013
Accepts healthy volunteers No
Gender All
Age group 15 Years to 17 Years
Eligibility Inclusion Criteria:

- Age 15-17

- Followed in the Stollery Pediatric Cardiology Clinic or the Northern Alberta Adult Congenital (NAACH) clinic

- Moderate or Complex Congenital Heart Disease (as defined by the 2001 Bethesda guidelines) or Acquired Heart Disease (cardiomyopathy (dilated, hypertrophic, or restrictive forms), Marfan's syndrome or rheumatic heart disease with cardiac involvement)

Exclusion Criteria:

- Developmental Delay, reading level below grade 6 based on patient or parent report

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Clinic-based Educational Intervention
This will involve a 60 minute interaction between the teen and an advanced practice nurse (APN) in the cardiology clinic. A MyHealth passport will be created covering the name of the teen's cardiac condition, previous cardiac interventions, and name and purpose of the teen's medications. Potential late cardiac complications and contact names and location of local adult CHD cardiologists will also be reviewed. Three scenarios regarding adolescent risk taking behaviors (written in the 3rd person) will be presented to the teen who will be asked what advice he/she would offer to the teen in each of those scenarios. The teen will be given a study email address and encouraged to contact the APN by email or text messaging with follow-up questions. If no contact is initiated after 1 week, the APN will email or text (based on preference) the youth, to discuss additional questions.

Locations

Country Name City State
Canada Stollery Children's Hospital Edmonton Alberta

Sponsors (3)

Lead Sponsor Collaborator
University of Alberta Stollery Children's Hospital Foundation, Women and Children's Health Research Institute, Canada

Country where clinical trial is conducted

Canada, 

References & Publications (3)

Mackie AS, Islam S, Magill-Evans J, Rankin KN, Robert C, Schuh M, Nicholas D, Vonder Muhll I, McCrindle BW, Yasui Y, Rempel GR. Healthcare transition for youth with heart disease: a clinical trial. Heart. 2014 Jul;100(14):1113-8. doi: 10.1136/heartjnl-201 — View Citation

Sawicki GS, Lukens-Bull K, Yin X, Demars N, Huang IC, Livingood W, Reiss J, Wood D. Measuring the transition readiness of youth with special healthcare needs: validation of the TRAQ--Transition Readiness Assessment Questionnaire. J Pediatr Psychol. 2011 Mar;36(2):160-71. doi: 10.1093/jpepsy/jsp128. Epub 2009 Dec 29. — View Citation

Warnes CA, Liberthson R, Danielson GK, Dore A, Harris L, Hoffman JI, Somerville J, Williams RG, Webb GD. Task force 1: the changing profile of congenital heart disease in adult life. J Am Coll Cardiol. 2001 Apr;37(5):1170-5. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Transition Readiness Assessment Questionnaire (TRAQ) Score The TRAQ is the most rigorously evaluated transition readiness questionnaire available and was developed in the USA. It has 29 items with two domains, self-management (16 items) and self-advocacy (13 ). The TRAQ is at a grade 5.7 reading level and uses a Likert scale. Each item is scored 1-5, with 1 being assigned for responses of "No, I do not know how" and a score of 5 assigned for responses of "Yes, I always do this when I need to." The TRAQ scores produced include an overall score and a subscale score. The overall score and the subscale scores are calculated simply by taking the average score across the items in the questionnaire (or subscale). The higher the score, the greater the perceived self-management or self-advocacy skills of the participant. The lower scores indicate the participant has a lower perceived level of self-management or self-advocacy. Baseline, 1 month and 6 months
Secondary MyHeart Score Change in patient knowledge of his/her CHD (MyHeart score), comparing baseline to 1 month and 6 months follow-up. The MyHeart scale was developed for this study and has a grade 4.6 reading level. It consists of seven short answer or multiple-choice questions. Given the heterogeneity of prior medical and surgical interventions and need for medications in adolescents with heart disease, the denominator for some questions varied from one participant to the next. Accordingly, each participant was assigned a percentage correct score (numerator/denominatorĂ—100) at each time point. Higher percentage correct score reflects better patient knowledge of his/her CHD Baseline, 1 month and 6 months
See also
  Status Clinical Trial Phase
Completed NCT01671566 - Interval Training in Adults With Congenital Heart Disease a Randomized Trial N/A
Recruiting NCT01421030 - Outcomes in Patients and Their Closest Relatives Treated for Congenital Heart Disease With Catheter Based or Surgical Techniques Phase 0
Withdrawn NCT00981591 - Inhaled Iloprost as an Adjunct to Inhaled Nitric Oxide in Pediatric Critical Care Patients Phase 1/Phase 2
Completed NCT01567579 - An Evaluation of Routine Developmental Follow-Up in Infants and Children With Congenital Heart Disease
Terminated NCT00208676 - Using Tissue Doppler/Synchronization to Determine Heart Function in Children With Congenital Heart Disease N/A
Completed NCT01941576 - Effects of rhBNP in Pediatrics After Corrective Repair of Tetralogy Of Fallot N/A
Completed NCT01475357 - Intestinal Function in Neonates With Complex Congenital Heart Disease N/A
Active, not recruiting NCT01227096 - Randomized Controlled Trial of the Effects of Electroacupuncture Preconditioning in Children Undergoing Cardiac Surgery N/A
Completed NCT01201486 - Use of Color Doppler in Routine Examination of Fetal Heart in Second Trimester N/A
Completed NCT00397514 - Assessing the Hemodynamic Benefits of Cardiac Resynchronization Therapy in Children Following Open-Heart Surgery N/A
Completed NCT02232399 - Is Levosimendan Superior to Milrinone Regarding Acute Kidney Injury After Cardiac Surgery for Congenital Heart Disease? Phase 2
Completed NCT05191654 - Investigation of Cardiopulmonary Parameters, Motor Development and Muscle Strength in DS With and Without CHD
Recruiting NCT06267859 - Development of Methods for Effective Treatment and Improvement of Common Somatic Diseases in Children Early Phase 1
Completed NCT02320669 - Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass Phase 3
Completed NCT01489475 - Plasma Angiopoietin Levels in Children Following Cardiopulmonary Bypass N/A
Withdrawn NCT00579358 - Molecular Basis of Congenital Heart Defects
Recruiting NCT01196182 - Congenital Heart Disease GEnetic NEtwork Study (CHD GENES)
Recruiting NCT03822442 - MRI to Predict Rejection and Failure in Transplant and Cardiomyopathy Patients
Recruiting NCT04382573 - Better Delineation of CDK13 Related Phenotype and Epigenetic Signature.
Completed NCT00450684 - Cardiac Resynchronization Therapy in Congenital Heart Defects Phase 2/Phase 3